NCT00257010View on ClinicalTrials.gov

A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches

PHASE3CompletedINTERVENTIONAL

Enrollment

447

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Migraine

Interventions

DRUG

Almotriptan Malate

Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain

Trial Locations (49)

Unknown

Mobile

Montgomery

Oxford

Mesa

Phoenix

Jonesboro

Little Rock

Santa Monica

Centennial

Denver

Loxahatchee Groves

Miami

Orlando

Tampa

West Palm Beach

Atlanta

Snellville

Idaho Falls

Chicago

Des Moines

Topeka

Witchita

Louisville

Ann Arbor

Columbia

Springfield

St Louis

Endwell

Mineola

Mount Vernon

Plainview

Raleigh

Cincinnati

Columbus

Oklahoma City

Philadelphia

Pittsburgh

Alcoa

Bristol

Germantown

Morristown

Nashville

Dallas

Fort Worth

Houston

San Antonio

San Marcos

Salt Lake City

Madison

All Listed Sponsors

collaborator

Ortho-McNeil Neurologics, Inc.

INDUSTRY

lead

Janssen-Ortho LLC

INDUSTRY

NCT00257010 - A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches | Biotech Hunter | Biotech Hunter